27 September 2024 Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector.
China’s National Medical Products Administration (NMPA) has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD). 27 September 2024
Chicago, USA-based ARCH Venture Partners revealed it has closed the ARCH Venture Fund XIII, a venture capital fund with more than $3 billion to support the founding and growth of early-stage biotechnology companies. 27 September 2024
US virology and immunology company Enanta Pharmaceuticals has given further weight to its claims to have the leading portfolio of potent respiratory syncytial virus (RSV) replication inhibitors 27 September 2024
Sage Therapeutics has announced that Biogen has terminated its partnership on the SAGE-324 program, following the recent failure of the drug in a Phase II study for the treatment of essential tremor. 27 September 2024
A US Food and Drug Administration advisory committee meeting has recommended restricting the use of PD-1 inhibitors, in a move which could affect blockbuster products such as Bristol Myers Squibb's Opdivo (nivolumab) and Merck & Co's Keytruda (pembrolizumab). 27 September 2024
The US Food and Drug Administration yesterday approved pharma major Bristol Myers Squibb’s Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. 27 September 2024
USA-based biotech funder and incubator Flagship Pioneering yesterday unveiled Mirai Bio, a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines. 27 September 2024
Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector. 27 September 2024
US drugmaker AbbVie has announced positive topline results from its pivotal Phase III TEMPO-1 trial for tavapadon as a monotherapy in early Parkinson's disease. 26 September 2024
Evaxion Biotech has entered into an option and license agreement with MSD (tradename of Merck & Co outside of the USA and Canada), for two pre-clinical vaccine candidates. 26 September 2024
Danish CNS specialist Lundbeck and US privately-held biotech Iambic Therapeutics today announced a strategic research collaboration to focus on discovery of a small molecule therapeutic for the treatment of migraine. 26 September 2024
The generics and biosimilars trade group, Medicines for Europe, has put out a strong message amid ongoing discussions on a European Union (EU) Critical Medicines Act. 26 September 2024
Pfizer (NYSE: PFE) has announced the withdrawal of Oxbryta (voxelotor), a treatment for sickle cell disease (SCD), from all global markets. 26 September 2024
US biotech major Amgen rolled out senior executives and a swish presentation in providing an update on two of its drugs in Phase III trials this week. 26 September 2024
US biotech Emergent BioSolutions revealed it has secured approximately $400 million in orders in 2024 and 2025 associated with its vaccinia, smallpox and mpox product portfolio. 26 September 2024
German drug discovery company Evotec has entered a technology development partnership with Danish drugmaker Novo Nordisk in cell therapy. 26 September 2024
Canada-based companies Imagia Cybernetics, AI-healthcare company, and Canexia Health have announced their planned merger, which is expected to close at the end of February, subject to shareholder approval. 11 February 2022
Members of the US House of Representatives have written a letter to Secretary of Health and Human Services (HHS) Xavier Becerra urging him to follow through with the Biden administration’s commitment to lowering exorbitant prescription drug costs. 11 February 2022
Already marketed and pipeline candidate Janus kinase (JAK) inhibitors have recently suffered setbacks in the USA, since the Food and Drug Administration found safety issues with the class of drugs and ordered Back Box label warnings. 11 February 2022
On Thursday, the Oncology Drug Advisory Committee (ODAC), an advisory panel of the US Food and Drug Administration, voted 14 to 1 that Eli Lilly and Innovent Biologics should conduct more trials of their anti-PD-1 antibody sintilimab in order to win approval for the drug in the USA. 11 February 2022
A freshly-approved coronavirus vaccine from Novavax has scored highly in a Phase III trial measuring effectiveness in adolescents aged 12 to 17. 11 February 2022
At the outset of the Pharmaceutical Strategy, European Commission President von der Leyen highlighted two clear priorities; to ensure Europe has the supply of affordable medicines to meet its needs and to support the European pharmaceutical industry to ensure that it remains an innovator and world leader. 11 February 2022
Shares of US biotech Seagen slumped more than 14% to $121.56 in early trading today, following the company’s release of financial results for the fourth quarter and year ended December 31, 2021, after markets closed on Wednesday. 10 February 2022
China's National Medical Products Administration (NMPA) has approved Benlysta (belimumab) for the treatment of adult patients with active lupus nephritis (LN) who are receiving standard of care. 10 February 2022
US biotech major Biogen and Swedish firm Xbrane Biopharma have entered into a commercialization and license agreement to develop, manufacture, and commercialize Xcimzane, a pre-clinical monoclonal antibody that is a proposed biosimilar referencing Cimzia (certolizumab pegol). 10 February 2022
Positive results from long-term, open-label extension studies demonstrated that olipudase alfa provided sustained improvement in lung function and reduction of spleen and liver volumes in adult and pediatric patients with non-central nervous system (non-CNS) manifestations of acid sphingomyelinase deficiency (ASMD). 10 February 2022
Aduhelm (aducanumab) co-developer Eisai has submitted its response to a much-anticipated reimbursement decision from the US Centers for Medicare & Medicaid Services (CMS). 10 February 2022
In this episode, we look at the potential impact of decentralized clinical trials, as increasing adoption of this kind of study forms part of a general movement towards greater use of innovative digital platforms for collecting and distributing clinical data. 10 February 2022
French immunotherapeutics-focussed biotech firm Transgene has appointed Steven Bloom as vice president, chief business officer with immediate effect. 10 February 2022
Following consultation with members – and heeding the concerns of the Consumers Health Forum (CHF) and patient groups – pharma trade group Medicines Australia reiterates its call to have finalization of the new National Medicines Policy (NMP) delayed until after the federal election. 10 February 2022
The US Food and Drug Administration said yesterday that it has taken new steps aimed at fostering the development of non-addictive alternatives to opioids to manage acute pain and decreasing exposure to opioids and preventing new addiction. 10 February 2022
The US regulator has accepted for Priority Review a bid to broaden the label for the antibody Dupixent (dupilumab) in moderate-to-severe atopic dermatitis. 10 February 2022
Shares of Danish CNS specialist Lundbeck closed down 7.4% at 148.55 kroner after it reported financial results for the fourth quarter and full year 2021. 10 February 2022
GlobalData has identified that drug pricing pressures are seen as the major hindrance to the growth of the pharmaceutical industry in 2022, forcing companies to reassess their pricing strategies and market focus. 10 February 2022